Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?
Development of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with GEM in search of regimens with improved survival ben...
Saved in:
| Main Authors: | Joanne Chiu, Thomas Yau |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/898931 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients
by: Sara De Dosso, et al.
Published: (2021-06-01) -
It doesn’t make sense, but we do: framing disease in an online metastatic breast cancer support community
by: Ariane B. Anderson
Published: (2019-08-01) -
Discovery of a novel RSK2 inhibitor for the treatment of metastatic pancreatic cancer
by: Chi-Hsiu Chung, et al.
Published: (2025-12-01) -
South Africa and national TB control: Are we making progress?
by: Gboyega A Ogunbanjo
Published: (2017-11-01) -
Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer
by: Sandra Doveson, et al.
Published: (2025-03-01)